Wall Street analysts predict that Kala Pharmaceuticals Inc (NASDAQ:KALA) will post earnings per share of ($0.37) for the current quarter, Zacks reports. Zero analysts have provided estimates for Kala Pharmaceuticals’ earnings, with the lowest EPS estimate coming in at ($0.43) and the highest estimate coming in at ($0.27). The firm is expected to report its next earnings report on Tuesday, February 20th.
According to Zacks, analysts expect that Kala Pharmaceuticals will report full year earnings of ($2.22) per share for the current fiscal year, with EPS estimates ranging from ($2.72) to ($1.95). For the next financial year, analysts forecast that the business will report earnings of ($1.93) per share, with EPS estimates ranging from ($2.19) to ($1.70). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that follow Kala Pharmaceuticals.
Several equities research analysts recently weighed in on KALA shares. Wedbush reaffirmed an “outperform” rating and issued a $46.00 price target on shares of Kala Pharmaceuticals in a research note on Friday, December 22nd. BidaskClub raised Kala Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, January 13th. Wells Fargo & Co reaffirmed a “buy” rating on shares of Kala Pharmaceuticals in a research note on Friday, January 5th. Finally, JPMorgan Chase & Co. set a $35.00 price target on Kala Pharmaceuticals and gave the stock a “buy” rating in a research note on Sunday, November 19th. One investment analyst has rated the stock with a sell rating, one has issued a hold rating and five have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $35.80.
In related news, major shareholder Orbimed Advisors Llc bought 25,000 shares of the business’s stock in a transaction dated Thursday, February 8th. The shares were purchased at an average cost of $12.93 per share, with a total value of $323,250.00. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Over the last three months, insiders bought 1,108,150 shares of company stock worth $15,772,394.
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Orbimed Advisors LLC purchased a new stake in shares of Kala Pharmaceuticals in the third quarter worth $54,251,000. JPMorgan Chase & Co. purchased a new stake in shares of Kala Pharmaceuticals in the third quarter worth $4,037,000. Bank of New York Mellon Corp purchased a new stake in shares of Kala Pharmaceuticals in the third quarter worth $540,000. Crestline Management LP purchased a new stake in shares of Kala Pharmaceuticals in the third quarter worth $888,000. Finally, Alyeska Investment Group L.P. purchased a new stake in shares of Kala Pharmaceuticals in the third quarter worth $2,907,000. 70.82% of the stock is currently owned by hedge funds and other institutional investors.
Shares of Kala Pharmaceuticals (NASDAQ KALA) traded down $0.27 during mid-day trading on Monday, reaching $14.77. The company had a trading volume of 75,231 shares, compared to its average volume of 508,252. The stock has a market capitalization of $357.83 and a PE ratio of -8.12. Kala Pharmaceuticals has a 12 month low of $11.81 and a 12 month high of $26.75. The company has a debt-to-equity ratio of 0.14, a quick ratio of 11.00 and a current ratio of 11.00.
COPYRIGHT VIOLATION WARNING: “Zacks: Brokerages Expect Kala Pharmaceuticals Inc (KALA) Will Post Earnings of -$0.37 Per Share” was originally published by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are viewing this piece on another publication, it was stolen and republished in violation of international copyright and trademark law. The original version of this piece can be viewed at https://www.dispatchtribunal.com/2018/02/19/zacks-brokerages-expect-kala-pharmaceuticals-inc-kala-will-post-earnings-of-0-37-per-share.html.
Kala Pharmaceuticals Company Profile
Kala Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapeutics through its nanoparticle-based Mucus Penetrating Particles, or MPP, technology. The Company’s initial focus is on the treatment of eye diseases. The Company’s product candidate includes KPI-121 1%, KPI-121 0.25% and MPP rTKI Program.
Get a free copy of the Zacks research report on Kala Pharmaceuticals (KALA)
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kala Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kala Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.